Therapeutic Asset Ratings

151 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
gw786034 Cancer	University Hospital, Bordeaux	P4	BB (65)
FENTANYL Cancer	M.D. Anderson Cancer Center	P3	BB (65)
gsk1120212 Cancer	Cancer Research UK	P2/3	BB (65)
PANITUMUMAB Cancer	Amgen	P4	BB (64)
Cyclophosphamide Cancer	National Cancer Institute (NCI)	P3	BB (64)
ETOPOSIDE Cancer	EMD Serono Research & Development Institute, Inc.	P3	B (63)
Capecitabine Cancer	University of Alabama at Birmingham	P3	B (62)
DEXAMETHASONE Cancer	Merck Sharp & Dohme LLC	P3	B (62)
Lipitor Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P3	B (62)
TESTOSTERONE UNDECYLATE Cancer	Aminex Therapeutics, Inc.	P3	B (62)
Vinorelbine Cancer	University Health Network, Toronto	P3	B (62)
Rasburicase Cancer	M.D. Anderson Cancer Center	P4	B (61)
Bms-907351 Cancer	Exelixis	P3	B (61)
PEGFILGRASTIM Cancer	Guangdong Provincial People's Hospital	P3	B (61)
PREDNISONE TABLETS Cancer	Exelixis	P3	B (61)
FILGRASTIM Cancer	Roswell Park Cancer Institute	P2	B (61)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Cancer	CStone Pharmaceuticals	P2	B (61)
Cytosin-Arabinosid Cancer	Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.	P3	B (60)
Dabrafenib Cancer	Cancer Research UK	P3	B (60)
Everolimus Cancer	Dana-Farber Cancer Institute	P3	B (60)
Acetylsalicylic Acid Cancer	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	P3	B (59)
Eribulin Cancer	GI Innovation, Inc.	P2	B (59)
ERIBULIN MONOMETHANESULFONATE Cancer	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	P1/2	B (59)
Sevoflurane Cancer	Hong Kong Children's Hospital	P4	B (58)
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE Cancer	Ankara City Hospital Bilkent	P3	B (58)

Showing 1 to 25 of 151 assets

PreviousPage 1 of 7Next